A phase II preoperative study of dasatinib, a multi-targeted tyrosine kinase inhibitor, in locally advanced “triple-negative” breast cancer patients

Authors
Category Primary study
JournalCancer Research
Year 2011
This article has no abstract
Epistemonikos ID: 0f166064a17d1ea303fe529fee99a73352bfe26f
First added on: Feb 05, 2025